Consulting services company ICF (NASDAQ:ICFI) reported on Monday the receipt of a new task order to support the US Agency for International Development (USAID) to provide infectious disease detection and surveillance support to affected lower and middle income countries worldwide.
The task order was awarded by the Bureau for Global Health, Office of Infectious Disease under the US General Services Administration's OASIS (One Acquisition Solution for Integrated Services) indefinite delivery, indefinite quantity contract.
Under a ceiling value of USD120m and a term of five years including one base year and four option years, ICF will provide direct implementation support services and capacity building assistance to countries to develop or improve their national diagnostic networks, laboratory systems and surveillance mechanisms so they are better able to detect and monitor the ever-growing number of emerging and re-emerging infectious diseases, including Ebola and multidrug-resistant tuberculosis.
As part of this contract, ICF will strengthen its partnership with USAID in helping it meet its vision of providing high-quality, specific technical assistance and support to countries to enable them to rapidly detect new and emerging infectious diseases and pathogens.
Additionally, ICF will support USAID's partnership within the US government to advance the Global Health Security Agenda, a worldwide effort to help build countries' capacity to help create a world safe and secure from infectious disease threats and elevate global health security as a national and global priority.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer